MannKind reported 201.15 in PE Price to Earnings for its fiscal quarter ending in March of 2026.





Pe Change Date
Adma Biologics 29.73 12.48 Dec/2025
BioCryst Pharmaceuticals 6.06 1.07K Dec/2025
Eli Lilly 40.27 0.06 Mar/2026
Halozyme Therapeutics 11.35 11.8 Mar/2026
MannKind 201.15 102.55 Mar/2026
Merck 16.52 2.6 Mar/2026
Novavax 2.01 1.07 Dec/2025
Novo Nordisk 13.92 4.91 Sep/2025
Pfizer 9.32 5.16 Mar/2026
Sanofi 11.84 0.14 Mar/2026
Xencor 29.92 3.22 Sep/2022